Skip to main content
IGC Pharma, Inc. logo

IGC Pharma, Inc. — Investor Relations & Filings

Ticker · IGC ISIN · US45408X3089 LEI · 529900TIWO8H06FQC983 US Professional, scientific and technical activities
Filings indexed 762 across all filing types
Latest filing 2016-02-16 Regulatory Filings
Country US United States of America
Listing US IGC

About IGC Pharma, Inc.

https://igcpharma.com/

IGC Pharma, Inc. is a clinical-stage biotechnology company focused on developing treatments for Alzheimer's disease. The company leverages artificial intelligence (AI) in its development process. Its lead candidate, IGC-AD1, is being evaluated in a Phase 2 clinical trial for treating agitation in patients with dementia due to Alzheimer's. The company's pipeline also includes TGR-63, a pre-clinical small molecule designed to inhibit amyloid plaque aggregation. Supporting its therapeutic development is MINT-AD, an AI-powered platform for the early detection of Alzheimer's and to improve the understanding of disease progression.

Recent filings

Filing Released Lang Actions
8-K Filing
Regulatory Filings
2016-02-16 English
10-Q Filing
Interim / Quarterly Report Q2 2016
2015-11-13 English
AMENDMENT TO FORM SC 13G
Major Shareholding Notification
2015-09-24 English
8-K
Regulatory Filings
2015-08-26 English
10-Q
Interim / Quarterly Report Q1 2016
2015-08-14 English
DEF 14A
Proxy Solicitation & Information Statement
2015-07-24 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.